Kardium Inc. is a rapidly growing medical solutions company that has developed an advanced system for the treatment of atrial fibrillation (AF), which affects more than 59 million people worldwide. The Globe® Mapping and Ablation System is the most complete solution for AF, offering single-shot pulmonary vein isolation, high-definition mapping, and atrial ablation – all in a single catheter. Founded in 2007 and headquartered in Vancouver, Canada, Kardium has been recognized as a top company to work for in BC, including recognition as Medical Technology Company of the Year in 2015 and 2021 by LifeSciences BC.
Kevin Chaplin - CEO
Kevin joined Kardium in 2008. He has been active in many areas at Kardium, including product development, marketing, clinical development, business development and financing. Prior to Kardium, Kevin held product management, marketing and technical positions at Kodak, Sierra Wireless and Accenture. He started his career working as an engineer at the deepest gold mine in the world. Kevin has a B.Sc. in Chemical Engineering from the University of Cape Town.
Doug Goertzen - President and COO
Doug is a co-founder of Kardium. Prior to Kardium, Doug held the position of General Manager, Proofing and Color at Eastman Kodak Company, and was responsible for the $55M worldwide proofing and colour business and a 130-person team. He held senior positions in service, development and management during his 12 years at Kodak and Creo Inc. (acquired by Kodak in 2005). He graduated with a B.A.Sc. in Electrical Engineering from Simon Fraser University.
Amos Michelson - Co-founder and Chairman
Amos was the Chief Executive Officer of Creo Inc. from 1995-2005, when it was purchased by Eastman Kodak Company. He joined Creo in 1991, serving in positions including Vice-President Business Strategy, Managing Director, and Chair of the Board of Directors until his appointment as CEO. Under his leadership, Creo grew to employ over 4,000 personnel and generate US$650M in annual revenue. Amos holds an MBA from Stanford Business School and a B.Sc. in Electrical Engineering from the Technion – Israel Institute of Technology.
Dave Rosa - Director
Dave is Executive Vice-President and Chief Business Officer at Intuitive. He joined the company in 1996 and has held leadership positions in commercial, engineering, clinical development, marketing, and product development. From 2015-19, he served as Executive Vice-President and Chief Commercial Officer. Prior to that, he held roles as Executive Vice-President and Chief Scientific Officer and Senior Vice-President, Scientific Affairs. Dave earned a B.S. in Mechanical Engineering from California Polytechnic University at San Luis Obispo. He also holds an M.S. in Mechanical Engineering from Stanford University.
Manuel Alba - Director
In 1993, Manuel joined Avigdor Willenz as co-founder of Galileo Technology, where he served as its President and as a director until its merger with Marvell Technology. In 2005, he and a group of fellow angel investors began to create and help grow technology start-ups. He is currently an investor and board member in several international private technology companies and has been a board member of various non-profit organizations in California. Manuel holds a BSEE from the National Polytechnic Institute in Mexico City, MS degrees in Computer Engineering and Engineering Management from the University of Southern California, and an MBA from Santa Clara University.
Ian Ihnatowycz - Director
Ian is CEO of First Generation Capital Inc., a private investment holding company. Formerly, he served as CEO of Acuity Investment Management Inc., which grew to assets of over $7.5B. Ian holds a B.Sc. from the University of Toronto, an MBA from the Ivey Business School, and earned the CFA and Chartered Director designations.
Prof. Hans Kottkamp - Medical Advisor
Prof. Kottkamp is the Head of the Department of Electrophysiology at Sana Hospital Benrath in Dusseldorf, Germany. He is an expert in the diagnosis and treatment of atrial fibrillation, and he focuses on catheter ablation of supraventricular and ventricular arrhythmias with special emphasis on ablation of atrial fibrillation. He has more than 150 publications in international journals and monographs, and is on the editorial board of the Journal of Cardiovascular Electrophysiology and Heart Rhythm. His clinical work deals with all aspects of interventional cardiac electrophysiology.
Dr. Vivek Reddy - Medical Advisor
Dr. Reddy is the Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and the Mount Sinai Health System, and The Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at Icahn School of Medicine at Mount Sinai. He leads a team of physicians and scientists to research and develop advanced therapies for cardiac arrhythmias, which includes atrial fibrillation and ventricular tachycardias.
Dr. Atul Verma - Medical Advisor
Dr. Verma is the Director of the Division of Cardiology and Isadore Rosenfeld Chair in Cardiology at McGill University. His main interests are in treatment of complex arrhythmias, particularly atrial fibrillation and ventricular tachycardia. He has served as Co-Chair of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee and as a writing member of the HRS/EHRA Consensus Document on Catheter Ablation of AF. He has published over 170 peer-reviewed articles.
Dan Gelbart - Co-Founder & Advisor
Dan is an inventor who has more than 100 U.S. patents to his name. He co-founded Creo Inc. in 1984 and served as President and then CTO until 2005, when Creo was sold to Kodak for US$1B. He holds an M.Sc. in Electrical Engineering from the Technion in Israel. Dan was twice awarded the British Columbia Science Council gold medal, as well as the Institute of Printing gold medal, and honorary doctorates from Simon Fraser University and the University of British Columbia.
Dr. Sam Lichtenstein - Co-Founder & Advisor
Dr. Lichtenstein holds numerous senior medical positions, including head of the UBC Division of Cardiovascular Surgery. He is a renowned practitioner and researcher in cardiovascular surgery and has made significant contributions to heart surgery techniques during his career.